Evidence map›Paper›PMID 41299521›Full record

ArticleJournal of translational medicine2025

Stigmasterol exerts antioxidant effects through activation of the Keap1/Nrf2 signaling pathway in Parkinson's disease model.

Yanfei Tong, Qi Qu, Zhiting Wan, Qi Luo, Ren-He Xu, Shaogang Qu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanfei TongDepartment of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Qi QuDepartment of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Zhiting WanDepartment of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Qi LuoGuangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
Ren-He XuCenter of Reproduction, Development and Aging, Cancer Center, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, SAR, Taipa, Macao SAR, 999078, China.
Shaogang QuDepartment of Neurology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, 341000, China. sgq9528@smu.edu.cn.ORCID http://orcid.org/0000-0002-0647-3701

Funding

National Natural Science Foundation of China 81870991Natural Science Foundation of Jiangxi Province 20232ACB206021Science and Technology Projects in Guangzhou 2024B03J1257
6 · The paper itself

Abstract

backgroundGiven that there is not yet a fully effective treatment for Parkinson's disease (PD), further research into therapeutic agents is necessary to enhance PD patients' clinical performance and quality of life. Stigmasterol (ST) exerts some pharmacological effects on the nervous system, such as antioxidant, anti-apoptosis, anti-inflammation, and modulation of autophagy, but its potential effects on PD are unclear. This study aimed to determine whether ST exerted neuroprotective benefits in a PD model and to clarify the underlying molecular mechanism.

methodsWe performed behavioral, immunohistochemical, immunofluorescence, western blot, and biochemical index assays in 1-methyl-4-phenylpyridinium (MPP

resultsWe found that ST in the PD model activated the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway and promoted the Nrf2 nuclear translocation. Additionally, it increased the antioxidant enzymes expression, thereby attenuating reactive oxygen species (ROS)-induced oxidative stress, which in turn, slowed the dopaminergic neuron loss by inhibiting apoptotic pathways, and improved the tyrosine hydroxylase (TH) protein expression, and helped reduce motor impairments in the PD mouse model.

conclusionsOur results indicate that ST has an antioxidant role in the PD model through activating the Keap1/Nrf2 signaling pathway, offering a theoretical foundation for its potential therapeutic use in PD treatment.

Indexed as

AntioxidantsKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Parkinson DiseaseSignal Transduction1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsApoptosisDisease Models, AnimalDopaminergic NeuronsMaleMiceMice, Inbred C57BLOxidative StressReactive Oxygen Species1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAntioxidantsKeap1 protein, mouseKelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseNF-E2-Related Factor 2Reactive Oxygen SpeciesDopaminergic neuronsKeap1/Nrf2 signaling pathwayOxidative stressParkinson’s diseaseStigmasterol

Identifiers

PMID41299521
PMCPMC12763839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.